Anti-Thymocyte Globulin (Thymoglobulin), Tacrolimus, and Sirolimus as Acute Graft-versus-Host Disease Prophylaxis for Unrelated Hematopoietic Stem Cell Transplantation

Lignende værker

• High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplantation Patients
  af: Al-Kadhimi, Zaid, et al.
  Udgivet: (2014)
• Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT
  af: Ratanatharathorn, V, et al.
  Udgivet: (2014)
• A phase II study of tacrolimus and thymoglobulin as graft-versus-host-disease prophylaxis in related donor allogeneic hematopoietic cell transplantation
  af: Modi, Dipenkumar, et al.
  Udgivet: (2018)
• Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention
  af: Al-Kadhimi, Z, et al.
  Udgivet: (2017)
• Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma
  af: Abidi, Muneer H., et al.
  Udgivet: (2012)